Trial of Psilocybin versus Escitalopram for Depression
If psilocybin is approved, how would it compare with a standard SSRI for someone like me — and what does this head-to-head trial's null primary result mean?
Well-supported by good-quality research. how we score evidence
Caveat on this rating: Investigators are prominent psychedelic-research advocates; blinding was imperfect in both arms. The null primary endpoint is often glossed over in media coverage.
Phase 3 complete; rolling NDA under FDA review, final module expected Q4 2026. Breakthrough Therapy designation 2018 (TRD) / 2019 (MDD).
In 59 adults with moderate-to-severe depression, two doses of psilocybin were not significantly better than 6 weeks of daily escitalopram on the primary depression score at week 6; secondary outcomes appeared to favor psilocybin but were not corrected for multiple comparisons, so no superiority claim is supported.
Worth asking
If psilocybin is approved, how would it compare with a standard SSRI for someone like me — and what does this head-to-head trial's null primary result mean?
Source
Trial of Psilocybin versus Escitalopram for Depression — Carhart-Harris R, et al. (2021)
Top-tier peer-reviewed journal
Read the source: https://doi.org/10.1056/NEJMoa2032994
DOI: 10.1056/NEJMoa2032994
How this was scored
- Study design
- Randomised controlled trial
- Funding
- Independently funded
- Published in
- Top-tier peer-reviewed journal
- Sample size
- 59
- Preregistered
- Yes
- Conflicts disclosed
- not recorded
- Independent of proponent
- not recorded
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Where we put this study in context
Questions
How strong is the evidence behind this?
Resolv rates this source "strong evidence". Well-supported by good-quality research. It scores 78 out of 100 on our published rubric. One caveat travels with that badge: Investigators are prominent psychedelic-research advocates; blinding was imperfect in both arms. The null primary endpoint is often glossed over in media coverage. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Trial of Psilocybin versus Escitalopram for Depression — Carhart-Harris R, et al. (2021). Published in: Top-tier peer-reviewed journal. DOI: 10.1056/NEJMoa2032994. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Randomised controlled trial. Funding: Independently funded. Independence from the proponent is not recorded. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is psilocybin FDA approved for this use?
No. Its current status is: Phase 3 trials. Phase 3 complete; rolling NDA under FDA review, final module expected Q4 2026. Breakthrough Therapy designation 2018 (TRD) / 2019 (MDD).
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.